IL2RA and neoplasm: Although CCL21 and anti-CD25 alone also significantly inhibited tumor growth after treatment, the combination therapy of CCL21 and anti-CD25 mAbs resulted in a more robust inhibition of tumor development, and had the most significant delay in tumor growth as determined by tumor volume after treatment initiation (Figure 2D) and tumor weight on day 9 when treatment was stopped (Figure 2E).